The Schistosomiasis Vaccine - It Is Time to Stand Up
Schistosomiasis is a severe parasitic disease, endemic in 74 developing countries with up to 600 million people, including many children, infected and 800 million at risk of contracting the disease following infection with Schistosoma mansoni, S. haematobium or S. japonicum. Disease burden is estima...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2015 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (82 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993547652804498 |
---|---|
ctrlnum |
(CKB)3710000000631135 (oapen)https://directory.doabooks.org/handle/20.500.12854/58943 (EXLCZ)993710000000631135 |
collection |
bib_alma |
record_format |
marc |
spelling |
Ahmad Ali Othman auth The Schistosomiasis Vaccine - It Is Time to Stand Up Frontiers Media SA 2015 1 electronic resource (82 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Schistosomiasis is a severe parasitic disease, endemic in 74 developing countries with up to 600 million people, including many children, infected and 800 million at risk of contracting the disease following infection with Schistosoma mansoni, S. haematobium or S. japonicum. Disease burden is estimated to exceed 70 million disability-adjusted life-years, and leads to remarkably high YLD (years lived with disability) rates. Even more importantly, people with schistosomiasis are highly susceptible to malaria, tuberculosis and hepatic and acquired immunodeficiency viruses. There is only one drug, praziquantel, currently available for treatment and it has high efficacy, low cost, and limited side effects. However, only 13% of the target population has received the drug, and those treated are at continuous risk of reinfection necessitating repeated drug administration and the emergence of drug resistant parasites is a constant threat. There currently is no vaccine. While the target of >40% protection has been achieved with some molecules such as excretory-secretory proteins including calpain, glyceraldehyde 3-phosphate dehydrogenase, and cysteine peptidases, very recent articles reiterate the findings published during the last 2 decades of the last century, contradicting the established data of the pioneers of schistosome biology. A consensus should be reached without delay, in order to propose collaborative independent experiments and proceed ahead to pre- and clinical trials with efficacious candidate vaccine molecules. The proposed plan aims to finally reach an objective and fruitful agreement , via inviting established and young researchers from the United States, Brazil, China, Australia, and Europe who are working with different vaccine antigens, adjuvants, and approaches for immunization against S. mansoni, S. haematobium, and S. japonicum. It is hoped that the forum will end with a very few candidate antigens and a consensus approach regarding target immune responses, thus leading to encouraging the World Health Organization and other international foundations to sponsor the development and implementation of the urgently required, yet still elusive, vaccine for preventing and eliminating the transmission of schistosomiasis. English Schistosomiasis Schistosoma mansoni Schistosoma haematobium Type 2 cytokines Vaccine Immune responses Schistosoma japonicum Vaccine candidates 2-88919-741-7 Donald McManus auth Rashika El Ridi auth |
language |
English |
format |
eBook |
author |
Ahmad Ali Othman |
spellingShingle |
Ahmad Ali Othman The Schistosomiasis Vaccine - It Is Time to Stand Up Frontiers Research Topics |
author_facet |
Ahmad Ali Othman Donald McManus Rashika El Ridi |
author_variant |
a a o aao |
author2 |
Donald McManus Rashika El Ridi |
author2_variant |
d m dm r e r rer |
author_sort |
Ahmad Ali Othman |
title |
The Schistosomiasis Vaccine - It Is Time to Stand Up |
title_full |
The Schistosomiasis Vaccine - It Is Time to Stand Up |
title_fullStr |
The Schistosomiasis Vaccine - It Is Time to Stand Up |
title_full_unstemmed |
The Schistosomiasis Vaccine - It Is Time to Stand Up |
title_auth |
The Schistosomiasis Vaccine - It Is Time to Stand Up |
title_new |
The Schistosomiasis Vaccine - It Is Time to Stand Up |
title_sort |
the schistosomiasis vaccine - it is time to stand up |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2015 |
physical |
1 electronic resource (82 p.) |
isbn |
2-88919-741-7 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT ahmadaliothman theschistosomiasisvaccineitistimetostandup AT donaldmcmanus theschistosomiasisvaccineitistimetostandup AT rashikaelridi theschistosomiasisvaccineitistimetostandup |
status_str |
n |
ids_txt_mv |
(CKB)3710000000631135 (oapen)https://directory.doabooks.org/handle/20.500.12854/58943 (EXLCZ)993710000000631135 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
The Schistosomiasis Vaccine - It Is Time to Stand Up |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField noLinkedField |
_version_ |
1787551692126945281 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03400nam-a2200385z--4500</leader><controlfield tag="001">993547652804498</controlfield><controlfield tag="005">20231214132824.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2015 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000000631135</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/58943</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000000631135</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ahmad Ali Othman</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The Schistosomiasis Vaccine - It Is Time to Stand Up</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (82 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Schistosomiasis is a severe parasitic disease, endemic in 74 developing countries with up to 600 million people, including many children, infected and 800 million at risk of contracting the disease following infection with Schistosoma mansoni, S. haematobium or S. japonicum. Disease burden is estimated to exceed 70 million disability-adjusted life-years, and leads to remarkably high YLD (years lived with disability) rates. Even more importantly, people with schistosomiasis are highly susceptible to malaria, tuberculosis and hepatic and acquired immunodeficiency viruses. There is only one drug, praziquantel, currently available for treatment and it has high efficacy, low cost, and limited side effects. However, only 13% of the target population has received the drug, and those treated are at continuous risk of reinfection necessitating repeated drug administration and the emergence of drug resistant parasites is a constant threat. There currently is no vaccine. While the target of >40% protection has been achieved with some molecules such as excretory-secretory proteins including calpain, glyceraldehyde 3-phosphate dehydrogenase, and cysteine peptidases, very recent articles reiterate the findings published during the last 2 decades of the last century, contradicting the established data of the pioneers of schistosome biology. A consensus should be reached without delay, in order to propose collaborative independent experiments and proceed ahead to pre- and clinical trials with efficacious candidate vaccine molecules. The proposed plan aims to finally reach an objective and fruitful agreement , via inviting established and young researchers from the United States, Brazil, China, Australia, and Europe who are working with different vaccine antigens, adjuvants, and approaches for immunization against S. mansoni, S. haematobium, and S. japonicum. It is hoped that the forum will end with a very few candidate antigens and a consensus approach regarding target immune responses, thus leading to encouraging the World Health Organization and other international foundations to sponsor the development and implementation of the urgently required, yet still elusive, vaccine for preventing and eliminating the transmission of schistosomiasis.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Schistosomiasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Schistosoma mansoni</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Schistosoma haematobium</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Type 2 cytokines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Vaccine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Immune responses</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Schistosoma japonicum</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Vaccine candidates</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88919-741-7</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Donald McManus</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rashika El Ridi</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:32:09 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2016-04-12 04:07:06 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338608490004498&Force_direct=true</subfield><subfield code="Z">5338608490004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338608490004498</subfield></datafield></record></collection> |